Related references
Note: Only part of the references are listed.Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Ralf Reilmann et al.
LANCET NEUROLOGY (2019)
Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease
Veronica Francardo et al.
NEUROTHERAPEUTICS (2019)
Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model
Ariel Ionescu et al.
CELL DEATH & DISEASE (2019)
Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor
Chelsy R. Eddings et al.
NEUROBIOLOGY OF DISEASE (2019)
Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques
Tom H. Johnston et al.
MOVEMENT DISORDERS (2019)
Untitled
NUKLEARMEDIZIN-NUCLEAR MEDICINE (2018)
Therapeutic approaches to Huntington disease: from the bench to the clinic
Nicholas S. Caron et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease
Susanna Waters et al.
JOURNAL OF HUNTINGTONS DISEASE (2018)
PET Imaging Evaluation of Four σ1 Radiotracers in Nonhuman Primates
Evan Baum et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice
Marta Garcia-Miralles et al.
JCI INSIGHT (2017)
Pridopidine for the treatment of Huntington's disease
Kathleen M. Shannon
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Pridopidine activates neuroprotective pathways impaired in Huntington Disease
Michal Geva et al.
HUMAN MOLECULAR GENETICS (2016)
Loss-of-function mutations in the SIGMAR1 gene cause distal hereditary motor neuropathy by impairing ER-mitochondria tethering and Ca2+ signalling
Elisa Gregianin et al.
HUMAN MOLECULAR GENETICS (2016)
Evaluation of the Enantiomer Specific Biokinetics and Radiation Doses of [18F]FluspidineA New Tracer in Clinical Translation for Imaging of σ1 Receptors
Mathias Kranz et al.
MOLECULES (2016)
Crystal structure of the human σ1 receptor
Hayden R. Schmidt et al.
NATURE (2016)
Biochemical Pharmacology of the Sigma-1 Receptor
Uyen B. Chu et al.
MOLECULAR PHARMACOLOGY (2016)
Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model
Ferdinando Squitieri et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2015)
The involvement of the sigma-1 receptor in neurodegeneration and neurorestoration
Karsten Ruscher et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2015)
Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic
Renzo Mancuso et al.
PROGRESS IN NEUROBIOLOGY (2015)
Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses
Kristoffer Sahlholm et al.
PSYCHOPHARMACOLOGY (2015)
Automation of the radiosynthesis and purification procedures for [18F]Fluspidine preparation, a new radiotracer for clinical investigations in PET imaging of σ1 receptors in brain
Aurelie Maisonial-Besset et al.
APPLIED RADIATION AND ISOTOPES (2014)
Distinctive In Vivo Kinetics of the New σ1 Receptor Ligands (R)-(+)- and (S)-(-)-18F-Fluspidine in Porcine Brain
Peter Brust et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Evaluation of P-glycoprotein (abcb1a/b) modulation of [18F]fallypride in MicroPET imaging studies
Markus Piel et al.
NEUROPHARMACOLOGY (2014)
Evaluation of metabolism, plasma protein binding and other biological parameters after administration of (-)-[18 F]Flubatine in humans
Marianne Patt et al.
NUCLEAR MEDICINE AND BIOLOGY (2014)
The dopamine stabilizers ACR16 and (-)-OSU6162 display nanomolar affinities at the sigma-1 receptor
K. Sahlholm et al.
MOLECULAR PSYCHIATRY (2013)
The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans
A. Hellden et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis
Amr Al-Saif et al.
ANNALS OF NEUROLOGY (2011)
Molecular imaging of σ receptors: synthesis and evaluation of the potent σ1 selective radioligand [18F]fluspidine
Steffen Fischer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Fitting Emax models to clinical trial dose-response data
Simon Kirby et al.
PHARMACEUTICAL STATISTICS (2011)
The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties
Tino Dyhring et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited
Vincent J. Cunningham et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2010)
The sigma-1 receptor chaperone as an inter-organelle signaling modulator
Tsung-Ping Su et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2010)
Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia:: An [18F]fallypride PET study
Gerhard Gruender et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization
Johan P. Rung et al.
JOURNAL OF NEURAL TRANSMISSION (2008)
Brain imaging of 18F-fallypride in normal volunteers:: Blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors
J Mukherjee et al.
SYNAPSE (2002)
Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain
N Tzourio-Mazoyer et al.
NEUROIMAGE (2002)